Hotelbuchung
Hotel Registration
Grußwort
Welcome address
Beteiligte Gesellschaften
Societies involved
DOG Information
DOG Information
Eröffnung des Kongresses
Opening Ceremony
Preise
Awards
Ablauf der Tagung 2003
General overview of congress
Lageplan der Räumlichkeiten
Map of Congress Center
Wissenschaftliche Themen
Scientific topics
Symposien
Symposia
Wissenschaftliches Programm
Scientific program
Posterpräsentationen
Poster Presentation
Kurse
Courses
Begleitende Veranstaltungen
Accompanying program
Arbeitssitzungen
Working sessions
Rahmenprogramm
Social program
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Industrieaussteller
Commercial exhibitors
Sponsoren
Sponsors
Impressum
DOG Homepage
Abstract
Abstract
Triamcinolone Acetonide Inhibits Neovascularization in an ROP Mouse Model in vivo and in vitro
Spandau U. H. M.1, Sauder G.1, Schubert U.2, Hammes H.-P.3
1Department of Ophthalmology and 3Department. of Internal Medicine, Faculty of Clinical Medicine Mannheim, Ruprecht-Karls-University of Heidelberg, Germany; 2Institute of Biochemistry, University of Giessen, Germany
Purpose: To evaluate the effect of crystalline triamcinolone acetonide on proliferating retinal endothelial cells in vivo and in vitro.
Method: Using bovine retinal endothelial cells, a sprouting assay with different concentrations of crystalline triamcinolone acetonide was performed. For in vivo analysis, a retinopathy of prematurity (ROP) model was used. Sixteen C57BL/J6 mice were exposed to 75% oxygen from postnatal day 7 to day 12 . On day 12, crystalline triamcinolone acetonide was intravitreally injected into one eye (study eye), and isotonic saline into the contralateral eye (control eye). On day 17, the mice were sacrificed and the eyes removed for quantitative analysis of preretinal neovascularizations. Four non-exposed mice served as negative control. Immuno-histochemistry was used to detect inflammatory changes in ROP lesions.
Results: In vitro sprouting assay revealed a dose-dependent inhibition of bovine retinal endothelial cells from 0.05 mg triamcinolone/ml (no inhibition) to 2 mg triamcinolone/ml (complete inhibition). The ROP model demo